Search

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
GET IN TOUCH

Enabling Faster Decisions: The Role of Guaranteed TAT in DMPK Programs

September 01, 2026

In lead optimization, every compound that advances does so because a team made a call, and that call is only as sound as the data behind it. DMPK studies are decision-enabling; they are active filters determining which molecules justify further investment and which should be eliminated before more resources are committed.

Timing is what separates a useful filter from an expensive one. DMPK data arriving after a synthesis round has already been designed validates a problem rather than preventing it. When medicinal chemistry and DMPK results cannot be reviewed together, the structure-activity relationship (SAR) picture remains incomplete. Teams either pause and wait, losing iteration time, or proceed on partial information, incurring compounding costs across a program.

Why Predictability Matters as Much as Speed

A single rapid assay result does not help a team that needs a complete ADME/PK package to make a compound progression decision. Teams require a coherent dataset across metabolic stability, permeability, plasma protein binding, and in vivo PK before the next design cycle can begin with confidence.

When teams know exactly when the data will arrive, they can schedule design reviews, align cross-functional discussions, and plan synthesis accordingly. Unpredictable turnaround times remove that planning certainty, stripping away the compounding velocity benefit that integrated DMPK is supposed to deliver.

The Challenge Behind Guaranteed TAT

Committing to a guaranteed turnaround time across a full DMPK workflow is harder than it appears. Most outsourced models rely on handoffs between separate functions: compound intake, in vitro ADME, in vivo PK, bioanalysis, and reporting. Even when individual assays complete on time, aggregate TAT becomes unpredictable due to fragmented coordination and isolated data silos. Guaranteed TAT requires that every step operates within a single connected infrastructure rather than a chain of independent service providers.

How Aragen Enables Guaranteed TAT

Aragen offers an integrated suite of in vitro ADME and in vivo PK studies spanning discovery to early development, backed by infrastructure built specifically to eliminate handoff delays:

  • High-Throughput Automation: Automated high-throughput screening, paired with Orbitrap and TOF MS/MS bioanalysis, delivers a consistent 5–7 working day assay-to-report TAT across full in vitro ADME panels, without compromising data quality or compound coverage.
  • Integrated In Vivo Supply Chain: Locally present breeding partners alongside an AAALAC-accredited vivarium remove external supply chain dependencies that cause study initiation delays.
  • Connected Governance: Aragen’s XLRATE™ project management platform centralizes tracking, logistics, and communication so client scientists can focus on high-priority decision-making rather than coordination overhead.

From Data Delivery to Program Velocity

When DMPK data arrives on time, every time, discovery teams do not just move faster. They make compound decisions with the confidence that comes from complete, current data. Aragen’s integrated teams carry this same TAT commitment from early hit-to-lead through preclinical IND-enabling studies, ensuring no context is lost at any stage.

Ready to define a guaranteed TAT commitment for your lead optimization program? Talk to Aragen’s DMPK team today.

FAQs

Guaranteed turnaround time in DMPK programs is a committed delivery window for complete assay-to-report data packages. Unlike estimated turnaround times, guaranteed TAT ensures that in vitro ADME and in vivo PK data arrive within a fixed window, typically 5–7 working days, eliminating workflow bottlenecks that slow lead optimization cycles.

Predictable data delivery allows medicinal chemistry and DMPK teams to maintain synchronized iteration cycles. When ADME/PK data arrives on a dependable schedule, project teams can align synthesis reviews, evaluate complete structure-activity relationship (SAR) profiles, and avoid making compound progression decisions based on partial or delayed information.

Aragen delivers a guaranteed 5–7 working day turnaround time from assay initiation to final report for core in vitro ADME panels and discovery in vivo PK studies. This is enabled by Biomek i7 high-throughput automation, Orbitrap and TOF MS/MS bioanalysis, and an on-site AAALAC-accredited vivarium with locally present breeding partners.

Aragen typically requires only few milligrams of compound to execute a comprehensive in vitro ADME screening panel, including metabolic stability, solubility, plasma protein binding, and permeability assays. This minimal material requirement enables early-stage screening without placing excessive demand on initial synthesis resources.

Traditional DMPK outsourcing models rely on sequential handoffs between separate functions, including compound management, assay execution, bioanalysis, and data reporting. When these steps operate without a shared project context or centralized tracking, coordination gaps accumulate and total turnaround times consistently exceed individual assay estimates.

Aragen's project management platform—XLRATE™ centralizes logistics, sample tracking, and communication across integrated drug discovery workflows. It connects client scientists directly with dedicated project management teams, ensuring transparent data access, eliminating coordination delays between functions, and maintaining consistent adherence to guaranteed TAT commitments.